The Taiwan Government Industrial Development Bureau awarded CellMax Life a $760,846 grant for its cancer detection platform.
CellMax Life is using the grant to increase automation and commercialization efforts for its early cancer circulating tumor cell detection platform CellMax CMx.
Here's what you should know:
1. The company is using its device initially to detect colorectal cancer.
2. The company wants to increase CRC screening compliance for high-risk populations and for people over 50 years old.
3. In high-risk patients, a clinical study showed the CMx Platform correctly identified patients with colorectal cancer 90 percent of the time.
4. President and CEO of CellMax Life Atul Sharan said in a release, "This is additional recognition that our CTC Technology is enabling early cancer detection in the high-growth cancer diagnostics area."
More articles on gastroenterology:
Boston Scientific continues to pour money into endoscopy — Why?
GI leader to know: Dr. Cynthia Wait of Illinois Gastroenterology Group
XBiotech discontinues its phase III trial & more — 6 GI company key notes